PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (the EOGBM1-18/ROSALIE study), in an oral presentation at the Society for Neuro-Oncology (SNO) 28th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023.

巴黎，2023年11月13日（GLOBE NEWSWIRE）-基于其独特的模仿平台开发用于固体和液体恶性肿瘤和炎性疾病的一流免疫调节药物的临床阶段公司Enterome今天宣布将提供更新的疗效数据来自EO2401联合nivolumab+/-bevacizumab的1/2期临床试验，在胶质母细胞瘤首次进展/复发的患者（EOGBM1-18/ROSALIE研究）中，于11月在加拿大不列颠哥伦比亚省温哥华召开的神经肿瘤学会（SNO）第28届年会上发表口头报告。15-192023。

Oral presentation details – Abstract CTIM-25 Title: EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study (NCT04116658) Presenting Author: Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School, and Clinical Director for Dana Farber Cancer Institute Session Name: Abstract Concurrent Session: Clinical Trials - Immunologic Session Date and Time: Friday, November 17, 2023, at 8:35 AM PST Location: Room 109-110 Link to abstract published in a supplement to Neuro-Oncology, the Official Journal of the Society for Neuro-Oncology, can be found here.

口头报告详情-摘要CTIM-25标题：EO2401肽免疫疗法+nivolumab+/-贝伐单抗治疗首次复发性胶质母细胞瘤：1/2期EOGBM1-18/ROSALIE研究（NCT04116658）作者：David Reardon教授，医学博士，教授哈佛医学院医学院，Dana-Farber癌症研究所临床主任会议名称：摘要同期会议：临床试验-免疫学会议日期和时间：2023年11月17日星期五，上午8:35 PST地点：109-110室链接至摘要发表于神经肿瘤学会官方期刊Neuro-Oncology的补充资料可以在这里找到。

The slides from the oral presentation will be available on Enterome’s website after the Meeting. About ROSALIE ROSALIE (EOGBM1-18) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab, Opdivo®) +/- bevacizumab for the treatment of patients with first progression/recurrence of glioblastoma.

会议结束后，口头报告中的幻灯片将在Enterome的网站上提供。关于ROSALIE ROSALIE（EOGBM1-18）是EO2401联合免疫检查点抑制剂（nivolumab，Opdivo®）+/-贝伐单抗治疗患者的多中心，开放标签，首次人体内1/2期研究首先进展/复发胶质母细胞瘤。

The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of the combination in 100 patients enrolled at 10 clinical sites in Europ.

该研究旨在评估该组合在Europ的10个临床地点登记的100名患者中的安全性，耐受性，免疫原性和初步功效。